Find clinical trials for Lung Cancer in New Haven, CT
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Lung Cancer trials near New Haven, CT, USA:
with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung ...
Phase 2
Hartford, Connecticut, United States of America and 8 other locations
chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osim ...
Phase 2
Commack, New York, United States and 16 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Port Jefferson, New York, United States and 83 other locations
metastatic NSCLC with an EGFR mutation. Both drugs work to target cancer cells with an EGFR mutation, and this targeting action could stop o...
Phase 2
Commack, New York, United States and 6 other locations
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).
Phase 3
New Haven, Connecticut, United States and 92 other locations
the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...
Phase 1, Phase 2
Stony Brook, New York, United States and 30 other locations
with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...
Phase 3
Port Jefferson Station, New York, United States and 210 other locations
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study...
Phase 2
New Haven, Connecticut, United States and 46 other locations
, early-stage non-small cell lung cancer....
Phase 2
New Haven, Connecticut, United States and 94 other locations
(PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung...
Phase 1
New Haven, Connecticut, United States and 14 other locations
Clinical trials
Research sites
Resources
Legal